JP2011157405A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157405A5
JP2011157405A5 JP2011116395A JP2011116395A JP2011157405A5 JP 2011157405 A5 JP2011157405 A5 JP 2011157405A5 JP 2011116395 A JP2011116395 A JP 2011116395A JP 2011116395 A JP2011116395 A JP 2011116395A JP 2011157405 A5 JP2011157405 A5 JP 2011157405A5
Authority
JP
Japan
Prior art keywords
dry powder
powder formulation
surface modifier
formulation
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011116395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011157405A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157405A publication Critical patent/JP2011157405A/ja
Publication of JP2011157405A5 publication Critical patent/JP2011157405A5/ja
Pending legal-status Critical Current

Links

JP2011116395A 2002-05-02 2011-05-24 肺感染の拡大を制限する処方物 Pending JP2011157405A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37732702P 2002-05-02 2002-05-02
US60/377,327 2002-05-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004500839A Division JP2005535581A (ja) 2002-05-02 2003-05-01 肺感染の拡大を制限する処方物

Publications (2)

Publication Number Publication Date
JP2011157405A JP2011157405A (ja) 2011-08-18
JP2011157405A5 true JP2011157405A5 (enExample) 2012-09-13

Family

ID=29401482

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004500839A Pending JP2005535581A (ja) 2002-05-02 2003-05-01 肺感染の拡大を制限する処方物
JP2011116395A Pending JP2011157405A (ja) 2002-05-02 2011-05-24 肺感染の拡大を制限する処方物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004500839A Pending JP2005535581A (ja) 2002-05-02 2003-05-01 肺感染の拡大を制限する処方物

Country Status (6)

Country Link
US (1) US8858917B2 (enExample)
EP (1) EP1531795A4 (enExample)
JP (2) JP2005535581A (enExample)
AU (1) AU2003243191B2 (enExample)
CA (1) CA2483917C (enExample)
WO (1) WO2003092654A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070053844A1 (en) * 2005-05-18 2007-03-08 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
US20100172845A1 (en) * 2007-05-29 2010-07-08 Board Of Regents Of The University Of Texas System Compositions and methods for treating mycobacterial infections
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
JP5909745B2 (ja) * 2010-11-12 2016-04-27 クール ファーマシューティカルズ ディベロップメント カンパニー 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬
US9504796B2 (en) * 2011-10-14 2016-11-29 The Trustees Of The Stevens Institute Of Technology Reducing ventilator-induced lung injury
US9693990B2 (en) 2011-10-14 2017-07-04 The Trustees Of The Stevens Institute Of Technology Use of rhodamine dyes to reduce alveolar surface tension
EP2819672A1 (en) 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalable dry powders
JP5478693B2 (ja) * 2012-03-23 2014-04-23 太平洋セメント株式会社 二次電池用正極活物質及びその製造方法
KR20220166879A (ko) 2012-06-21 2022-12-19 노쓰웨스턴유니버시티 펩티드 접합된 입자
KR20250076678A (ko) 2013-03-13 2025-05-29 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 염증 치료용 면역-변형된 입자
HRP20192270T4 (hr) 2013-08-13 2024-03-01 Northwestern University Konjugirane čestice peptida
US10391151B2 (en) 2015-06-29 2019-08-27 The Trustees Of The Stevens Institute Of Technology Dilute surfactant or isolated surfactant protein solution for the reduction of surface tension in the lung

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37053A (en) 1862-12-02 Improved me at-cutter
DE3229179C2 (de) * 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4899914A (en) 1988-11-04 1990-02-13 Ciba-Geigy Corporation Method for producing a sterile preservative-free aerosol saline solution
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
JP3961029B2 (ja) 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
CA2145948A1 (en) * 1994-04-06 1995-10-07 Wendell A. Ehrhart Floor covering having a (meth)acrylated, highly ethoxylated, aromatic polyester wear layer
US5863563A (en) 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
AU701042B2 (en) * 1995-02-28 1999-01-21 Aventisub Llc Pharmaceutical composition for piperidinoalkanol compounds
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
WO1997029738A1 (en) * 1996-02-16 1997-08-21 The Administrators Of The Tulane Educational Fund Methods and compositions for treating eustachian tube dysfunction by inhalation
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
ATE287257T1 (de) * 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
US5883084A (en) 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
JP2004513071A (ja) * 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法
US6669959B1 (en) * 2000-07-18 2003-12-30 Aeropharm Technology Incorporated Modulated release particles for lung delivery
WO2002009574A2 (en) 2000-08-01 2002-02-07 Shofner Engineering Associates, Inc. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatment of the respiratory tract
JP2004517127A (ja) 2000-12-21 2004-06-10 ネクター セラピューティックス ポリエン抗真菌剤の肺送達
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
WO2003094900A1 (en) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
WO2005094869A1 (en) * 2004-03-30 2005-10-13 Malcolm King Compositions and methods for improved mucus function
US8627821B2 (en) * 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
US9708895B2 (en) 2013-05-07 2017-07-18 Halliburton Energy Services, Inc. Intrawell fluid injection system and method

Similar Documents

Publication Publication Date Title
JP2011157405A5 (enExample)
JP2011116788A5 (enExample)
JP2010248206A5 (enExample)
JP2014526447A5 (enExample)
Tan et al. Novel approaches for the treatment of pulmonary tuberculosis
HK1219096A1 (zh) 抗篡改的药物制剂
WO2011031564A3 (en) Methods and systems for dosing and coating inhalation powders onto carrier particles
JP2013544781A5 (enExample)
AU2018253545A1 (en) Microcrystalline diketopiperazine compositions and methods
JP2016512494A5 (enExample)
JP2012503668A5 (enExample)
JP2010537989A5 (enExample)
JP2020527377A5 (enExample)
WO2007123793A3 (en) Swellable particles for drug delivery
JP2014509313A5 (enExample)
JP2019151649A5 (enExample)
WO2010138884A3 (en) Respiratory delivery of active agents
JP2015509788A5 (enExample)
JP2009512663A5 (enExample)
WO2013038267A8 (en) Tamper resistant pharmaceutical formulations
JP2012131827A5 (enExample)
JP2013534227A5 (enExample)
JP2015505541A5 (enExample)
WO2012051426A3 (en) Aggregate nanoparticulate medicament formulations, manufacture and use thereof
HRP20230863T1 (hr) Inhalacijska formulacija rapamicina, namijenjena liječenju stanja povezanih sa starenjem